Vaccinex, Inc. (VCNX)

NASDAQ: VCNX · IEX Real-Time Price · USD
0.601
+0.011 (1.93%)
At close: Jan 27, 2023, 4:00 PM
0.635
+0.033 (5.57%)
After-hours: Jan 27, 2023, 6:07 PM EST
1.93%
Market Cap 30.00M
Revenue (ttm) 50,000
Net Income (ttm) -19.37M
Shares Out 49.88M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 63,686
Open 0.568
Previous Close 0.590
Day's Range 0.568 - 0.620
52-Week Range 0.410 - 2.280
Beta 1.07
Analysts Buy
Price Target n/a
Earnings Date Mar 29, 2023

About VCNX

Vaccinex, Inc., a clinical-stage biotechnology company, focuses on treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phas... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Maurice Zauderer
Employees 39
Stock Exchange NASDAQ
Ticker Symbol VCNX
Full Company Profile

Financial Performance

In 2021, Vaccinex's revenue was $900,000, an increase of 44.00% compared to the previous year's $625,000. Losses were -$22.38 million, -22.43% less than in 2020.

Financial Statements

News

The 3 Best Biotech Stocks Under $1 to Buy for January

While biotech may be the next big thing, making money through it isn't easy. Indeed, investing in biotech stocks is often more of an art than a science.

Other symbols: ATOSSPPI
1 day ago - InvestorPlace

Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology

Surface Oncology initiates clinical trial with antibody discovered using Vaccinex's ActivMAb® Antibody Discovery Platform Surface Oncology initiates clinical trial with antibody discovered using Vacci...

2 weeks ago - GlobeNewsWire

Vaccinex Announces $3.8 Million Private Placement

ROCHESTER, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative d...

2 months ago - GlobeNewsWire

Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update

Continued Progress in Pepinemab Oncology and Neurology Clinical Programs Continued Progress in Pepinemab Oncology and Neurology Clinical Programs

2 months ago - GlobeNewsWire

Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer

New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment Options New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combinat...

2 months ago - GlobeNewsWire

Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs

Promising initial responses in continuing Phase 1b/2 KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

5 months ago - GlobeNewsWire

Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer's Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer's Disease

ROCHESTER, N.Y., July 29, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative d...

6 months ago - GlobeNewsWire

Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET

ROCHESTER, N.Y., May 25, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative di...

8 months ago - GlobeNewsWire

Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update

Excellent Progress in Pepinemab Clinical Programs

9 months ago - GlobeNewsWire

Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery

ActivMAb technology to generate Complex Membrane Antigen Virus is a valuable drug discovery tool for difficult-to-drug targets ActivMAb technology to generate Complex Membrane Antigen Virus is a valua...

9 months ago - GlobeNewsWire

Vaccinex Reports 2021 Financial Results and Provides Corporate Update

Promising responses in Phase 1b segment of the open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC);

10 months ago - GlobeNewsWire

Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Meta

ROCHESTER, N.Y., March 09, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative ...

11 months ago - GlobeNewsWire

Vaccinex, Inc. to Present at CHDI's 17th Annual HD Therapeutics Conference Meeting

Poster Presentation: Combination immunotherapy and HTT-lowering in humanized HD mice, Wednesday, March 2, 2022 Poster Presentation: Combination immunotherapy and HTT-lowering in humanized HD mice, Wed...

1 year ago - GlobeNewsWire

Vaccinex And 4 Other Penny Stocks Bought By Insiders

The unemployment rate in the Eurozone dropped to a record low of 7% in December from a revised 7.1% level in the previous month, helping the STOXX Europe 600 Index record gains this morning. Investors...

Other symbols: ONCTPFMT
1 year ago - Benzinga

Vaccinex Announces $6.6 Million Private Placement

Participants include a syndicate of existing and new shareholders Contributes to total of $10.1 million in new equity financing for January, 2022

1 year ago - GlobeNewsWire

Vaccinex Posts Two Complete Responses In Pepinemab Combo Trial In Head & Neck Cancer

Vaccinex Inc shares are gaining after the Company reported interim response data in the Phase Ib segment of the KEYNOTE-B84 study.

1 year ago - Benzinga

Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer

ROCHESTER, N.Y., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer ...

1 year ago - GlobeNewsWire

Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

In-person and virtual Presentation: November 10-14th, 2021 In-person and virtual Presentation: November 10-14th, 2021

1 year ago - GlobeNewsWire

Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer's Disease (CTAD) Meeting

Live Presentation: Thursday, Nov. 11, 2021 Live Presentation: Thursday, Nov. 11, 2021

1 year ago - GlobeNewsWire

Vaccinex Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Enrollment underway in combination Phase 1b/2 study of pepinemab with KEYTRUDA® in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

1 year ago - GlobeNewsWire

Vaccinex, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference

Virtual Dates: November 18 th – 19 th , 2021

1 year ago - GlobeNewsWire

Vaccinex to Present at the Virtual Huntington's Study Group Meeting on November 4-6, 2021

Presentation to highlight expanded post-hoc subgroup analysis of the SIGNAL Phase 2 Huntington's Disease (HD) trial suggesting a cognitive benefit in patients with mildly advanced disease Presentation...

1 year ago - GlobeNewsWire

Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit

ROCHESTER, N.Y., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and...

1 year ago - GlobeNewsWire